AGÕæÈ˹ٷ½

Group 1 Automotive (GPI) Form 144 filing: An insider intends to sell up to 525 common shares via Fidelity Brokerage Services on the NYSE on or about 29 Jul 2025. At the recent reference price the sale is valued at $219,975, implying roughly $419/share. With 12.94 million shares outstanding, the transaction equals just 0.004 % of the company’s equity.

The shares were acquired on 2 Jan 2025 through a stock-award compensation plan; no cash purchase was involved. The filer reports no additional sales during the past three months and certifies not possessing undisclosed adverse information about the issuer.

Given the very small size relative to daily trading volume and total float, the filing appears to be a routine liquidity event and is unlikely to exert material pressure on GPI’s share price or corporate control.

Jaguar Health (JAGX) has filed a Form S-3 to register up to 1,409,732 common shares for resale by existing investors. The stock derives from (i) 481,150 shares underlying 6 % convertible Replacement Notes issued 24 Jun 2025 (conversion price $5.535�$5.555, maturity 30 Jan 2026) and (ii) 928,582 shares issuable on cash or cash-less exercise of accompanying warrants (exercise price $2.70, 18-month term). At the 23 Jul 2025 close of $2.38 the warrant strikes sit 13 % above market while the note conversion price is >130 % above market. If fully converted/exercised the new shares would expand the current 1.914 million share float by roughly 74 %, creating a sizeable overhang.

The company will not receive proceeds from secondary sales; only a full cash exercise of all warrants could raise ~$2.5 million, earmarked for working capital. The filing follows several recent financings (March convertible notes and May registered direct offering) and occurs alongside an active GI-focused drug pipeline led by crofelemer (FDA-approved Mytesi, multiple Phase 2/3 programs, orphan designations) and the October 2024 U.S. launch of Gelclair for oral mucositis. While pipeline breadth offers optionality, near-term investors must weigh dilution risk and potential price pressure from selling stockholders against the modest capital infusion possible from warrant exercises.

Q2-25 snapshot: Revenue grew 5.2% YoY to $2.05 bn; gross margin expanded 120 bps to 39.9%, driving a 9.6% rise in operating earnings to $354.6 m. Diluted EPS from continuing operations climbed to $2.03 (+14%), but a $0.01 loss from discontinued ESG operations kept total diluted EPS flat at $2.02.

First-half trends: Sales advanced 2.2% to $3.92 bn and operating cash flow strengthened 25% to $369.8 m. Interest expense fell 21% while the effective tax rate held at ~20%. Segment mix remained favorable: Pumps & Process Solutions posted a 30.6% margin and Clean Energy & Fueling revenue jumped 18%. Restructuring charges totaled $21.8 m.

Balance sheet & capital moves: Cash declined to $1.26 bn after $658 m of M&A (Sikora, Cryo-Mach, ipp) and $41 m in share repurchases; long-term debt increased to $3.07 bn, yet interest-coverage is solid at 68×. Goodwill and intangibles rose to $7.27 bn as Dover continues its bolt-on strategy.

Strategic actions & risks: Acquisitions broaden the high-margin Pumps portfolio, while the 2024 ESG divestiture generated minor post-closing losses. A $58.9 m jury verdict tied to ESG could become a liability, though no charge was recorded. No guidance was provided.

Dimensional Fund Advisors LP (DFA) has filed a Schedule 13G indicating that, as of 30 June 2025, it beneficially owns 1,572,330 shares of Boston Omaha Corp ("BOC"), representing 5.1 % of the company’s outstanding common stock. The institutional investor reports sole voting power over 1,540,879 shares and sole dispositive power over the full 1,572,330-share position, with no shared voting or dispositive authority.

DFA, a Delaware limited partnership and SEC-registered investment adviser, explains that the shares are held across multiple mutual funds, commingled trusts and separate accounts for which it or its subsidiaries act as adviser or sub-adviser. While DFA may exercise voting and investment discretion, it expressly disclaims beneficial ownership in excess of the requirements of Section 13(d).

Crossing the 5 % ownership threshold triggers this disclosure and signals a modest increase in institutional ownership in BOC. Because DFA is predominantly a passive, quantitative manager, the filing does not suggest an activist agenda or an intention to influence control. Nevertheless, additional institutional sponsorship can enhance liquidity, broaden research coverage and potentially support the share price through index-related demand.

Key numeric details

• Date of event: 30 June 2025
• Shares owned: 1,572,330
• Percent of class: 5.1 %
• Sole voting power: 1,540,879
• Sole dispositive power: 1,572,330

Overall, the Schedule 13G is an informative but routine ownership disclosure that underscores growing passive interest in Boston Omaha without materially altering corporate governance or near-term strategy.

Filing type: Schedule 13D/A (Amendment No. 1) for Tian Ruixiang Holdings Ltd. (Ticker: TIRX). The amendment updates ownership data following a change in the issuer’s total outstanding shares.

Reporting persons:

• Mufang Gao (individual)
• Unitrust Holdings Ltd.
• Plenty Holdings Company Ltd.
• ES-Shining Unity Holdings Ltd.

Aggregate beneficial ownership (economic):

• Mufang Gao (combined across the three entities) â€� 3,250,900 shares, representing 2.65 % of the Class A share class.
• Unitrust Holdings â€� 2,008,900 shares (1.64 %).
• Plenty Holdings â€� 540,000 shares (0.45 %).
• ES-Shining Unity Holdings â€� 702,000 shares (0.58 %).

Holdings comprise (i) Class A ordinary shares, (ii) 1,050,000 Class B ordinary shares that carry 600 votes per share, and (iii) rights to purchase up to 1,009,800 additional Class A shares via warrants/options. All Class B shares are convertible 1-for-1 into Class A shares at the holder’s option.

Reason for amendment: the only change is the recalculation of ownership percentages based on the issuer’s newly reported 120,757,154 Class A shares outstanding as of 30 Jun 2025. No new share purchases or sales were reported in the preceding 60 days.

Governance implications: Although Gao’s economic stake is modest, the super-voting Class B shares materially enhance his voting influence. The complex multi-entity structure centralises dispositive and voting power in Gao, who is the sole director and controlling shareholder of each reporting entity.